Skip to Main Content

Try STAT+ TODAY

Month: September 2021

Most Read

Politics Rachel Cohrs

STAT Plus: Biden administration favors insurers over doctors, hospitals in controversial new surprise billing regulations

The Readout LOUD Adam Feuerstein and Meg Tirrell

Listen: Health equity ‘tourism,’ an $11B biopharma acquisition, & a bony Covid protest

In the Lab Andrew Joseph

STAT Plus: Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer

Exclusive Rachel Cohrs and Nicholas Florko

STAT Plus: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

Pharmalot Ed Silverman

STAT Plus: Appeals court rules FDA ‘arbitrarily and capriciously’ approved a rare disease drug

STAT Staff

Who telehealth isn’t reaching & Apple looks past A-fib

Biotech Matthew Herper

STAT Plus: With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant

Health Ed Silverman

Virtual Event: The evolving landscape for biosimilars

All Coverage

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Run on ivermectin tablets leaves less for livestock; Pfizer Covid-19 shot for kids may not come until November

Biotech Adam Feuerstein

STAT Plus: Editas CRISPR treatment improved vision for one patient, but not others, early data show

Pharmalot Ed Silverman

STAT Plus: As lawsuits mounted, Purdue cultivated conversations with a controversial addiction policy group

First Opinion Podcast Patrick Skerrett

Listen: Revisiting Uché Blackstock on leaving academic medicine

First Opinion William F. Haning, III

Overdose prevention sites can save lives and promote recovery. We must be willing to try them

Health Tech Hyacinth Empinado

STAT Plus: Watch: The tedious process of training computers to think about medicine, explained

Pharmalot Ed Silverman

STAT Plus: Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited

Pharmalot Ed Silverman

STAT Plus: FDA tells drug makers to redo studies run by two contract research firms due to data integrity issues

Politics Nicholas Florko

The government’s Covid-19 response will continue in a shutdown, but health agencies will face major staff shortages

Health Andrew Joseph

Side effect rates from a third Covid-19 vaccine dose similar to those after second shot, early data indicate

Health Tech STAT Staff

STAT Plus: Behind Epic’s algorithm to detect sepsis before it progresses

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Sanofi ends work on mRNA Covid-19 vaccine; Biogen seeks fast FDA approval of another Alzheimer’s drug

Health Nicholas St. Fleur and Usha Lee McFarling

STAT Plus: STAT+ Conversation: How medicine’s biggest journals are confronting racism

Biotech Kate Sheridan

STAT Plus: Graduate students launch an entrepreneurship program to bring new faces to biotech

Biotech Adam Feuerstein

STAT Plus: Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

First Opinion C.K. Wang

Paying participants isn’t the way to improve clinical trial recruitment